Drugs / F230
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06899815 | May 2025 → Jul 2026 overdue | pulmonary hypertension | Beijing Continent Pharmaceutical Co, Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06899815 ↗ |
| Action | Inhibit | “F230 had the same in vitro activity as the endothelin antagonist on the market” NCT06899815 ↗ |
| Modality | Small molecule | “new Class 1 chemical drug” NCT06899815 ↗ |
| Route | Oral | “F230 tablets or placebo were taken orally on an empty stomach” NCT06899815 ↗ |